NOsocomial Dissemination Risk of SARS-Cov2

NCT04339881 | Completed

• 1 other identifier: APHP200417
• Study Type: observational
• Target: 2,523
• Locations: 1 country
• Sites: 1

Brief Summary

To date, in France, in the context of the SARS Cov2 pandemic,both the number of affected subjects and the number of severe forms requiring hospital care are increasing. Several nosocomial transmission clusters have already been identified in hospitals (both pediatric and adult) but there is still limited data on the nosocomial spread of SARS-Cov2. This nosocomial transmission affects both patients and caregivers. It is important to understand the spread of the virus within the hospital. This will help to optimize procedures to prevent transmission to caregivers and hospitalizedpatients not infected with SARS Cov2, and more generally this will contribute to control the spread of SARS Cov2 in the community

Conditions

Sars-CoV2

Outcome Measures

Primary Outcomes (1)

• Understanding the dissemination of SARS Cov2 in hospital

  In each unit, during 2 days, Patients and all staff (caregivers, administrative, students…) will carry an individualsensorwhich will regularly measure the proximity between 2 sensors

  2 days

Secondary Outcomes (1)

• Optimizing hospital strategies to prevent transmission to caregivers and not infected hospitalized patients with SARSCov2

  8 weeks

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Working caregivers and hospitalized patients in care services dedicated or not to SARS Cov2 (including resuscitation services) in both adult and pediatric hospitals. Investigator will be interested in both adult and child services because the latter present a pauci-symptomatic form so the dynamics of transmission can be different.

You may qualify if:

• Informed of the purpose of the study and having expressed his non-opposition or of a relative (if the patient's state of health does not allow it)
• Hospitalized in one of the participating departments
• Informed of the objective of the study and having expressed his no opposition
• Having daily contact with patients hospitalized in participating departments
• Informed of the purpose of the study and having expressed his non-opposition
• Having daily contacts with patients hospitalized in the participating departments

You may not qualify if:

• Refuse to participate

Sponsors & Collaborators

• Assistance Publique - Hôpitaux de Paris: lead

Study Sites (1)

Didier Guillemot

Garches, France

Location

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Target Duration: 2 Days
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 6, 2020
• First Posted: April 9, 2020
• Study Start: April 17, 2020
• Primary Completion: July 10, 2020
• Study Completion: July 12, 2020
• Last Updated: November 23, 2020

Record last verified: 2020-04

Locations

FR (1)